[1. Mangiola M, Marrari M, Feingold B, Zeevi A. Significance of Anti-HLA Antibodies on Adult and Pediatric Heart Allograft Outcomes. Frontiers in Immunology. 2017;8(4).10.3389/fimmu.2017.00004526944828191005]Search in Google Scholar
[2. Freystaetter K, Andreas M, Bilban M, Perkmann T, Kaider A, Masetti M, et al. The recipient’s heme oxygenase-1 promoter region polymorphism is associated with cardiac allograft vasculopathy. Transpl Int. 2017;30(5):510-8.10.1111/tri.1293528186648]Search in Google Scholar
[3. Nakamura K, Inami M, Morio H, Okuma K, Ito M, Noto T, et al. AS2553627, a novel JAK inhibitor, prevents chronic rejection in rat cardiac allografts. European Journal of Pharmacology. 2017;796:69-75.10.1016/j.ejphar.2016.12.02527993641]Search in Google Scholar
[4. Colvin Monica M, Cook Jennifer L, Chang P, Francis G, Hsu Daphne T, Kiernan Michael S, et al. Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management. Circulation. 2015;131(18):1608-39.10.1161/CIR.000000000000009325838326]Search in Google Scholar
[5. Polyakova V, Hein S, Kostin S, Ziegelhoeffer T, Schaper J. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. Journal of the American College of Cardiology. 2004;44(8):1609-18.10.1016/j.jacc.2004.07.02315489093]Search in Google Scholar
[6. Aharinejad S, Krenn K, Zuckermann A, Schäfer R, Gmeiner M, Thomas A, et al. Serum Matrix Metalloprotease-1 and Vascular Endothelial Growth Factor–A Predict Cardiac Allograft Rejection. American Journal of Transplantation. 2009;9(1):149-59.10.1111/j.1600-6143.2008.02470.x19067665]Search in Google Scholar
[7. Calé R, Almeida M, Gonçalves P, Rebocho MJ, Raposo L, Teles R, et al. Complicações da biópsia endomiocárdica após transplante cardíaco. Um mal menor. Revista Portuguesa de Cardiologia. 2012;31(2):159-62.10.1016/j.repc.2011.12.00622222062]Search in Google Scholar
[8. Michel RP, Berry GJ. Pathology of Transplantation: A Practical Diagnostic Approach: Springer International Publishing; 2016.10.1007/978-3-319-29683-8]Search in Google Scholar
[9. Buszko M, Cardini B, Oberhuber R, Oberhuber L, Jakic B, Beierfuß A, et al. Differential depletion of total T cells and regulatory T cells and prolonged allotransplant survival in CD3Ɛ humanized mice treated with polyclonal anti human thymocyte globulin. PLOS ONE. 2017;12:e0173088.10.1371/journal.pone.0173088533625428257450]Search in Google Scholar
[10. Deng MC. The AlloMap™ genomic biomarker story: 10 years after. Clinical Transplantation. 2017;31(3):e12900.10.1111/ctr.1290028256042]Search in Google Scholar
[11. Yerly P RS, Nobile A, Aubert V, Tozzi PG, Yarol N, Vogt P, Hullin R & Pascual M. Time-Dependent Specificity of Immunopathologic (C4d-CD68) and Histologic Criteria of Antibody-Mediated Rejection for Donor-Specific Antibodies and Allograft Dysfunction in Heart Transplantation. Transplantation. 2015;99(3):586-93.10.1097/TP.000000000000024624983305]Search in Google Scholar
[12. Li L, Duan X, Wang H, Wang Q, Lu Y, Yan C, et al. Acute cellular rejection and antibody-mediated rejection in endomyocardial biopsy after heart transplantation: A retrospective study from a single medical center. International Journal of Clinical and Experimental Pathology. 2017;10:4772-9.]Search in Google Scholar
[13. Bayliss J BM, Leet A, Stein AN, Thomson NM & McLean CA.. Late onset antibody mediated rejection and endothelial localization of vascular endothelial growth factor are associated with development of cardiac allograft vasculopathy. Transplantation. 2008;86(7): 991-7.10.1097/TP.0b013e318186d73418852667]Search in Google Scholar
[14. Cheung K, Ma L, Wang G, Coe D, Ferro R, Falasca M, et al. CD31 signals confer immune privilege to the vascular endothelium. Proceedings of the National Academy of Sciences. 2015;112(43):E5815..10.1073/pnas.1509627112462937926392551]Search in Google Scholar
[15. Di Francesco A, Fedrigo M, Santovito D, Natarelli L, Castellani C, De Pascale F, et al. MicroRNA signatures in cardiac biopsies and detection of allograft rejection. The Journal of Heart and Lung Transplantation. 2018;37(11):1329-40.10.1016/j.healun.2018.06.01030174164]Search in Google Scholar
[16. Suzuki J-i, Isobe M, Kawauchi M, Endoh M, Amano J, Takamoto S. Altered expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in acutely rejected myocardium and coronary arteriosclerosis in cardiac allografts of nonhuman primates. Transpl Int. 2000;13(2):106-13.10.1111/j.1432-2277.2000.tb01049.x]Search in Google Scholar
[17. Campbell LG, Ramachandran S, Liu W, Shipley JM, Itohara S, Rogers JG, et al. Different Roles for Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9 in the Pathogenesis of Cardiac Allograft Rejection. American Journal of Transplantation. 2005;5(3):517-28.10.1111/j.1600-6143.2005.00744.x15707406]Search in Google Scholar
[18. Vanhoutte D, van Almen GC, Van Aelst LN, Van Cleemput J, Droogne W, Jin Y, et al. Matricellular proteins and matrix metalloproteinases mark the inflammatory and fibrotic response in human cardiac allograft rejection. Eur Heart J. 2013 Jul;34(25):1930-41.10.1093/eurheartj/ehs375405125923139380]Search in Google Scholar